Literature DB >> 1736535

Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins.

J Taylor1, R Weinberg, J Tartaglia, C Richardson, G Alkhatib, D Briedis, M Appel, E Norton, E Paoletti.   

Abstract

The development of canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) is described. Inoculation of the CPV-MV recombinants into avian or nonavian tissue culture substrates led to the expression of authentic MVF and MVHA as determined by radioimmunoprecipitation and surface immunofluorescence. In contrast to avian-derived tissue culture, no productive replication of the CPV recombinant was evident in tissue culture cells derived from nonavian origin. On inoculation of dogs, a species restricted for avipoxvirus replication, the recombinants elicited a protective immune response against a lethal canine distemper virus (CDV) challenge. The level of MV neutralizing antibodies and the level of protection induced against CDV challenge achieved by the host-restricted CPV vector were equivalent to that obtained by vaccinia virus vectors expressing the same MV antigens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1736535     DOI: 10.1016/0042-6822(92)90321-f

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  32 in total

Review 1.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

2.  Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo.

Authors:  Fatema A Legrand; Paulo H Verardi; Kenneth S Chan; Yue Peng; Leslie A Jones; Tilahun D Yilma
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-10       Impact factor: 11.205

3.  Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.

Authors:  José Luis Nájera; Carmen Elena Gómez; Elena Domingo-Gil; María Magdalena Gherardi; Mariano Esteban
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine.

Authors:  Reuben K Soi; Fred R Rurangirwa; Travis C McGuire; Paul M Rwambo; James C DeMartini; Timothy B Crawford
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

5.  Development of a challenge-protective vaccine concept by modification of the viral RNA-dependent RNA polymerase of canine distemper virus.

Authors:  D Silin; O Lyubomska; M Ludlow; W P Duprex; B K Rima
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

6.  Immunosorbent assay based on recombinant hemagglutinin protein produced in a high-efficiency mammalian expression system for surveillance of measles immunity.

Authors:  F Bouche; W Ammerlaan; F Berthet; S Houard; F Schneider; C P Muller
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

Review 7.  Non-replicating expression vectors: applications in vaccine development and gene therapy.

Authors:  K J Limbach; E Paoletti
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

8.  Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.

Authors:  J C Ramírez; M M Gherardi; M Esteban
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

9.  Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice.

Authors:  James F Papin; Paulo H Verardi; Leslie A Jones; Francisco Monge-Navarro; Aaron C Brault; Michael R Holbrook; Melissa N Worthy; Alexander N Freiberg; Tilahun D Yilma
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-23       Impact factor: 11.205

10.  Functional analysis of N-linked glycosylation mutants of the measles virus fusion protein synthesized by recombinant vaccinia virus vectors.

Authors:  G Alkhatib; S H Shen; D Briedis; C Richardson; B Massie; R Weinberg; D Smith; J Taylor; E Paoletti; J Roder
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.